{"url":"https://lda.senate.gov/api/v1/filings/f53c346b-ace2-4d12-96fa-e7dfc4fbb5c4/","filing_uuid":"f53c346b-ace2-4d12-96fa-e7dfc4fbb5c4","filing_type":"RR","filing_type_display":"Registration","filing_year":2012,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f53c346b-ace2-4d12-96fa-e7dfc4fbb5c4/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mark Lenker","dt_posted":"2012-03-17T14:10:29.207000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"355 I St. SW","registrant_address_2":"S-524","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":400888599,"url":"https://lda.senate.gov/api/v1/registrants/400888599/","house_registrant_id":null,"name":"THE LENKER GROUP LLC","description":"Government relations consulting","address_1":"355 I St. SW","address_2":"S-524","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK LENKER","contact_telephone":"+1 202-203-0490","dt_updated":"2022-04-06T16:07:16.794843-04:00"},"client":{"id":196014,"url":"https://lda.senate.gov/api/v1/clients/196014/","client_id":12,"name":"SHIRE PLC","general_description":"Pharmaceutical and biotech company","client_government_entity":false,"client_self_select":false,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2012-02-01"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"PDUFA, BSUFA, Life Sciences Jobs Investment Act, orphan drugs, health care reform implementation, drugs shortages, DEA quotaa, exclusivity periods, pharmaceutical and biotech issues related legislation, biosimilars guidance","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":55998,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"LENKER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"PDUFA, BSUFA, Life Sciences Jobs Investment Act, orphan drugs, health care reform implementation, drugs shortages, DEA quotaa, exclusivity periods, pharmaceutical and biotech issues related legislation, biosimilars guidance","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":55998,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"LENKER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}